John Caldwell

John Caldwell
achieved although comparable continuing customer earnings financial fourth growth improving last lower order period previous program progress quarter reflecting results revenue third wins
Our fourth quarter results demonstrate our continuing progress in improving our financial results. Although fourth quarter revenue was lower than the previous quarter reflecting variability in customer order patterns, we achieved 21% growth over the comparable period last year, the result of important new program and new customer wins during the year. It was also the third consecutive quarter of earnings growth.
depending holiday lie season tastes
It's going to be a choppy holiday season for retailers. There will be haves and have-nots depending on where consumers' tastes lie for the season.
earnings economic good growth looking market quarter remain solid underlying
The underlying fundamentals of the market still remain very healthy. We are looking at good solid earnings growth in the first quarter and economic growth that has bounced back.
concern element hours
There is always a heightened element of concern during early-morning hours of darkness.
business costs
We have to be competitive. The business is too cutthroat to have our costs out of line.
data driven economic either energy focus higher increased potential refute support
With the increased focus on the potential of an economic slowdown, driven by the higher energy prices, anything that comes out of the economic data to either support or refute that is going to be key.
care concern details headline investors larger overall reports unless
There is a headline concern with some of these larger companies, but the overall reports have still been very good. In many cases, investors don't care about the details unless they see it show up in the end.
care favorable happening health largest noticeable overall
There are noticeable recoveries. Just in the health care sector, the DRG index is outperforming the overall market, and Pfizer is the largest component. Clearly, there's something favorable happening in that group, but it's not the only one.